Laminil to Present at Animal Health Investment Forum

Companies presenting at the forum have raised nearly $130 million. Several have also received licensing agreements or distribution contracts. Read more

Laminil a big success at laminitis conference

Laminil was presented at the poster session and was well received by veterinarians, researchers and representatives of animal health companies from around the globe. Read more

Laminil data collection has been completed

To vets and horse owners: Data collection has been completed, and we are restricted by the FDA in what we can do with an investigational drug. Read more


Laminil is an injectable drug developed to halt the inflammatory response and laminitis cascade of acute laminitis and active chronic laminitis.

Laminil is designed to inhibit inflammatory mediators and other chemicals from being released from the mast cell in excess. When the inflammatory mediators are not released in excess, then the laminitis cascade is broken/halted. This allows the horse to start healing, though healing may take time.

Laminil is an investigational drug going through the FDA approval process. It is being tested around the world at major veterinary clinics.

Laminil has shown promise with all types of laminitis, such as insulin resistance, equine metabolic syndrome, grain overload, grass founder, trauma and single limb laminitis.

Laminil is a prescribed injectable drug administered by veterinarians via limb perfusion.

If you would like to receive information about Laminil, please contact Willowcroft Pharm Inc.

Willowcroft Pharm Inc.
820 Grape Street
Denver, CO 80220
Phone: (303) 875-7402

Winston happy a year after Laminil treatment

Winston’s owner has posted an update on the gelding on Facebook. The horse just celebrated his 18th birthday and is doing well.

Laminil saves jumper that developed into grade 4 sinker

This 10-year-old Oldenburg grand prix show jumper developed laminitis in October 2013 from stress and heat and failed to improve. The horse deteriorated to an OBEL grade 4 sinker.

Before and after video of laminitis case following joint injections

This horse developed laminitis in June 2013 after receiving joint injections. The post-treatment video was taken four days after treatment with Laminil.

Before and after video of weight-bearing case of laminitis

This horse developed a case of weight-bearing laminitis in September 2013. The post-treatment video was taken four weeks after treatment with Laminil.

Video of Pal the palomino, plus emotional words from his owner

“This is one of about six videos we shot today and they all show the same thing … success! The way things started back in October of last year, I would have never thought we would come this far …”

Laminil case study of Winston from May 2013

This 17-year-old gelding developed laminitis on May 6, 2013. By the next day, he didn’t want to walk. He was treated with Laminil on May 10. His owner reported on May 11 that he nearly dragged her out of the stall.

Laminil case study from May 2013

This gray horse had an acute case of laminitis in May 2013 and was treated with Laminil. Here is new video from August 2013 of the horse trotting soundly and showing off his slimmer figure.

Before and after video, 2011

This dark dun quarter horse had grade 4 laminitis, the most painful grade, in August 2011. It was treated with Laminil by a licensed vet and was sound three days later. Watch the before and after video.

Before and after video, 2013

This horse developed laminitis in April 2013. His discomfort is evident as he moves past the camera in the first video. He improved four days after infusion of Laminil.

Some laminitis statistics

There are more than 9 million horses in the United States. Annually, about 3 to 4 percent of those horses will develop a case of laminitis. Worldwide, there are hundreds of thousands of additional cases of laminitis per year.

Willowcroft Pharm